Breaking News: BioCryst’s Orladeyo (Berotralstat) Receives Approval from Israeli Ministry of Health
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of Health RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO® (berotralstat) to prevent attacks of hereditary angioedema (HAE) in adults and pediatric…